Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies
José Javier Morales‐Núñez, José Francisco Muñóz-Valle, Andrea Carolina Machado-Sulbarán, Saúl Alberto Díaz-Pérez, Paola Carolina Torres-Hernández, Beatríz Verónica Panduro-Espinoza, Jonathan Adrián Gallegos-Díaz de Leon, Carlos David Munguía-Ramirez, Jorge Hernández‐Bello
Topics & Concepts
ReactogenicityVirologyNeutralizing antibodyMedicineVaccinationCoronavirus disease 2019 (COVID-19)AntibodySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyImmunogenicityInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesCOVID-19 Clinical Research Studies